可疑(LI-RADS 4)肝脏病灶患者的临床结局
本文旨在描述多中心队列中LI-RADS 4肝脏病灶患者的临床结局,指出LR-5对肝细胞癌的阳性预测值超过95%,而LR-3或LR-4不确定结节在临床实践中常见、肝细胞癌风险异质且管理差异大,此前已报告LR-3病灶的年肝细胞癌发生率为8.4例/100人年,但LR-4病灶的自然史仍不确定。
要点
- LR-5病灶对肝细胞癌的阳性预测值超过95%。
- LR-3或LR-4不确定结节在临床实践中常见,肝细胞癌风险异质且管理差异大。
- 此前多中心队列报告LR-3病灶肝细胞癌年发生率为8.4例/100人年,LR-4自然史仍不确定。
核心结论
- 本文旨在多中心队列中描述LI-RADS 4肝脏病灶患者的临床结局。
- LR-4病灶的自然史仍不确定。
研究设计与样本
- 多中心队列研究,对象为LI-RADS 4肝脏病灶患者。
主要发现
- LR-5病灶对肝细胞癌的阳性预测值超过95%。
- LR-3或LR-4不确定结节在临床实践中常见,与异质性肝细胞癌风险相关,且实践管理差异大。
- 此前多中心肝硬化患者队列中LR-3病灶肝细胞癌年发生率为8.4例/100人年。
关键数值与推荐
- LI-RADS将高危患者肝脏病灶按恶性和肝细胞癌风险分类,LR-5病灶对肝细胞癌的阳性预测值超过95%。
- LR-3或LR-4为不确定肝脏结节。
临床怎么用
- 筛查结果异常者须接受多期计算机断层扫描(CT)或磁共振成像(MRI)诊断评估。
局限性
- LR-4病灶的自然史仍不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular cancer (HCC) surveillance is associated with increased curative treatment and improved survival, underscoring its importance in patients with cirrhosis.1 Surveillance is 1 step in a larger HCC screening continuum, and those with abnormal screening results must undergo diagnostic evaluation with multiphase computed tomography (CT) or magnetic resonance imaging (MRI).2 The Liver Imaging Reporting and Data System (LI-RADS) classifies liver observations in at-risk patients based on risk of malignancy and HCC, with LR-5 observations having a positive predictive value exceeding 95% for HCC. However, indeterminate liver nodules (ie, LR-3 or LR-4) are commonly observed in clinical practice, associated with heterogenous HCC risk, and have large variations in practice management.3,4 We previously reported the natural history of LR-3 observations in a multicenter cohort of patients with cirrhosis, demonstrating a high annual incidence for HCC development of 8.4 cases per 100 person-years;5 however, the natural history of LR-4 observations remains uncertain. Herein, we aimed to characterize clinical outcomes in patients with LR-4 observations in a multicenter cohort.
引用
- Onyirioha K, Joshi S, Burkholder D, et al. Clinical Outcomes of Patients With Suspicious (LI-RADS 4) Liver Observations. Clin Gastroenterol Hepatol. 2022. PMID: 35413448. doi:10.1016/j.cgh.2022.03.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。